Clinical Trial

Low Dose IL-2 for the Treatment of Crohn's Disease

Name: Low Dose IL-2 for the Treatment of Crohn's Disease — clinical trial record (NCT04263831)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to determine the safety and maximum effective dose (MED) of Interleukin-2 in subjects with moderate-to-severe crohn's disease.

Protocol Amendment History 1 change

notable Primary completion pushed: 2026-12-31 -> 2027-07-01 2026-07-30

Trial Details

NCT Number	NCT04263831
Lead Sponsor	Boston Children's Hospital Collaborators: National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Brigham and Women's Hospital
Conditions	Crohn Disease
Enrollment	30 participants
Start Date	2021-03-11
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-03